Cathie Wood’s ARK Investment Management made significant trades, emphasizing AI-led biotechnology and crypto while reducing exposure to consumer tech and electric vehicles. Recursion Pharmaceuticals (RXRX) emerged as a key focus, with ARK purchasing over 2.8 million shares worth $13.4 million, reflecting Wood’s belief in AI-driven drug discovery. RXRX’s stock performance has been lackluster, but recent clinical trial data has boosted sentiment. Recursion projects financial stability with a cash runway through 2027. Despite ongoing losses, analysts anticipate narrowing losses and revenue growth for RXRX. Wall Street recently upgraded RXRX stock due to positive clinical data, signaling potential for significant growth. Analysts give RXRX a consensus “Moderate Buy” rating with an average price target suggesting a 60.6% upside. Cathie Wood’s increased buying activity in RXRX highlights the long-term potential of the stock, but caution is advised due to technical signals and valuation. RXRX presents a high-risk, high-reward opportunity for patient investors.

Read more at Yahoo Finance: Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here?